Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | GYPA | P02724 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704224 | 1.00 | SLC6A2 (0.41) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL7156144 | 1.00 | SLC6A2 (0.41) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL6701050 | 1.00 | SLC6A2 (0.41) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL7642620 | 0.91 | SLC6A2 (0.44) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL7154227 | 0.91 | SLC6A2 (0.44) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL7066247 | 0.90 | SLC6A2 (0.39) | SLC6A2TSHRCYP2C19ALDH1A1PDE4D | |
| SCHEMBL8062413 | 0.86 | SSTR1 (0.45) | SLC6A2TSHRCYP2C19LGALS8 | |
| SCHEMBL7066725 | 0.83 | SLC6A2 (0.37) | SLC6A2TSHRCYP2C19PDE4DLGALS8 | |
| SCHEMBL19658823 | 0.83 | SLC6A2 (0.45) | SLC6A2LGALS8 | |
| SCHEMBL19652045 | 0.83 | SLC6A2 (0.45) | SLC6A2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800742-B2 | Method for producing β-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | AJINOMOTO CO., INC. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1260516-A1 | Method for producing a beta-D-ribofuranose derivative or an optical isomer thereof | Ajinomoto Co., Inc. (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187942-A1 | Method for producing beta-D-ribofuranose derivatives or optical isomers thereof | DERA, RNGTT, DUT | SLC6A2 3722/4885TSHR 1849/4885CYP2C19 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.